69 related articles for article (PubMed ID: 20715931)
41. Plasma Metabolomics Biosignature According to HIV Stage of Infection, Pace of Disease Progression, Viremia Level and Immunological Response to Treatment.
Scarpellini B; Zanoni M; Sucupira MC; Truong HM; Janini LM; Segurado ID; Diaz RS
PLoS One; 2016; 11(12):e0161920. PubMed ID: 27941971
[TBL] [Abstract][Full Text] [Related]
42. Ensemble clustering of longitudinal bivariate HIV biomarker profiles to group patients by patterns of disease progression.
Lynch ML; DeGruttola V
Int J Data Sci Anal; 2022; 14(3):305-318. PubMed ID: 35528805
[TBL] [Abstract][Full Text] [Related]
43. Early rapid decline in CD4 count reversed by splenectomy in HIV infection.
McKernan AM; Hay CR
Haemophilia; 1995 Jan; 1(1):67-9. PubMed ID: 27214224
[No Abstract] [Full Text] [Related]
44. Post-migration acquisition of HIV: Estimates from four European countries, 2007 to 2016.
Yin Z; Brown AE; Rice BD; Marrone G; Sönnerborg A; Suligoi B; Sasse A; Van Beckhoven D; Noori T; Regine V; Delpech VC
Euro Surveill; 2021 Aug; 26(33):. PubMed ID: 34414881
[TBL] [Abstract][Full Text] [Related]
45. Low Postseroconversion CD4
Palm AA; Lemey P; Jansson M; Månsson F; Kvist A; Szojka Z; Biague A; da Silva ZJ; Rowland-Jones SL; Norrgren H; Esbjörnsson J; Medstrand P
mBio; 2019 Jan; 10(1):. PubMed ID: 30622192
[TBL] [Abstract][Full Text] [Related]
46. Previously Unidentified Single Nucleotide Polymorphisms in HIV/AIDS Cases Associate with Clinical Parameters and Disease Progression.
Anokhin VV; Bakhteeva LB; Khasanova GR; Khaiboullina SF; Martynova EV; Tillett RL; Schlauch KA; Lombardi VC; Rizvanov AA
Biomed Res Int; 2016; 2016():2742648. PubMed ID: 28050553
[TBL] [Abstract][Full Text] [Related]
47. CXCR4-using HIV variants in a cohort of Black men who have sex with men: HIV Prevention Trials Network 061.
Chen I; Huang W; Connor MB; Frantzell A; Cummings V; Beauchamp GG; Griffith S; Fields SD; Scott HM; Shoptaw S; Del Rio C; Magnus M; Mannheimer S; Tieu HV; Wheeler DP; Mayer KH; Koblin BA; Eshleman SH
HIV Clin Trials; 2016 Jul; 17(4):158-64. PubMed ID: 27300696
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of rapid progressors in HIV infection as an extreme phenotype.
Olson AD; Guiguet M; Zangerle R; Gill J; Perez-Hoyos S; Lodi S; Ghosn J; Dorrucci M; Johnson A; Sannes M; Moreno S; Porter K;
J Acquir Immune Defic Syndr; 2014 Sep; 67(1):15-21. PubMed ID: 24872130
[TBL] [Abstract][Full Text] [Related]
49. The natural history of HIV infection.
Sabin CA; Lundgren JD
Curr Opin HIV AIDS; 2013 Jul; 8(4):311-7. PubMed ID: 23698562
[TBL] [Abstract][Full Text] [Related]
50. Immunogenic and tolerogenic signatures in human immunodeficiency virus (HIV)-infected controllers compared with progressors and a conversion strategy of virus control.
Whittall T; Peters B; Rahman D; Kingsley CI; Vaughan R; Lehner T
Clin Exp Immunol; 2011 Nov; 166(2):208-17. PubMed ID: 21985367
[TBL] [Abstract][Full Text] [Related]
51. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection.
Fischl MA
AIDS; 1999 Sep; 13 Suppl 1():S49-59. PubMed ID: 10546785
[TBL] [Abstract][Full Text] [Related]
52. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
53. Low postseroconversion CD4 count and rapid decrease of CD4 density identify HIV+ fast progressors.
Audigé A; Taffé P; Rickenbach M; Battegay M; Vernazza P; Nadal D; Speck RF;
AIDS Res Hum Retroviruses; 2010 Sep; 26(9):997-1005. PubMed ID: 20715931
[TBL] [Abstract][Full Text] [Related]
54. Immunologic marker paths for seroconversion: single determinations of immunoglobulin A and beta 2-microglobulin are not adequate to estimate time of HIV infection. Multicohort Analysis Project Workshop. Part II.
AIDS; 1994 Jul; 8(7):923-33. PubMed ID: 7946101
[TBL] [Abstract][Full Text] [Related]
55. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
Clin Infect Dis; 2005 Aug; 41(3):361-72. PubMed ID: 16007534
[TBL] [Abstract][Full Text] [Related]
56. Relationship between CD38 expression on peripheral blood T-cells and monocytes, and response to antiretroviral therapy: a one-year longitudinal study of a cohort of chronically infected ART-naive HIV-1+ patients.
Almeida M; Cordero M; Almeida J; Orfao A
Cytometry B Clin Cytom; 2007 Jan; 72(1):22-33. PubMed ID: 17051525
[TBL] [Abstract][Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
